Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients was launched today in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

31 Aug 2009

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Researchers today published promising results for a drug that could lead to a replacement for the very effective but difficult-to-use blood thinner Coumadin (sold generically as Warfarin), currently taken by millions of Americans to reduce their risk of stroke.

31 Aug 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

A common antibiotic can function as an "off switch" for a gene therapy being developed for Parkinson's disease, according to University of Florida researchers writing online in advance of September's Molecular Therapy.

29 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Researchers find link between asymptomatic PAD and cardiovascular events among stroke and TIA patients

Measuring circulation in the ankle using a device similar to a blood pressure cuff can help identify asymptomatic peripheral artery disease (PAD) in stroke and transient ischemic attack (TIA) survivors, a group at much higher risk of subsequent cerebrovascular events, according to a study in Stroke: Journal of the American Heart Association.

28 Aug 2009

NIH panel releases report on the pertinence of family health history information in improving health

Though most Americans are familiar with completing a questionnaire about their family health history when visiting health care providers, an independent panel was convened by the National Institutes of Health this week to critically assess exactly what we know and what we need to learn about how this process relates to improving health.

28 Aug 2009

Joint Commission urges health care leaders to prevent errors by taking the zero-defect approach

A new Joint Commission Sentinel Event Alert issued today urges health care leaders to step up efforts to prevent errors by taking the zero-defect approach used in other high-risk industries such as aviation and nuclear energy.

28 Aug 2009

Leicester research reveals the detrimental effects of Beta blockers on central aortic pressures

A University of Leicester-led study may have uncovered the reason why Beta-blockers are less effective at preventing stroke in older people with high blood pressure, when compared to other drugs for high blood pressure.

28 Aug 2009

Kingston General Hospital adopts Sentinelle Medical's new breast imaging system through HTAIP

Dr. Morris (Mickey) Milner, President and CEO of The Health Technology Exchange (HTX), announced the successful adoption of Sentinelle Medical's new breast imaging system by Kingston General Hospital (KGH), through the HTX's Health Technology Assessment and Implementation Program (HTAIP), a program funded by the Ontario Ministry of Research and Innovation.

28 Aug 2009

New rule from CMS for improving stroke patient care in hospitals

A new rule from the U.S. Centers for Medicare and Medicaid Services (CMS Final FY 2010 Rule) focuses on improving stroke patient care in hospitals. Beginning 2010, hospitals submitting Medicare claims for stroke must let CMS know if they participate in a database registry for stroke care, such as that maintained by the American Heart Association/American Stroke Association's Get With The Guidelines-Stroke (GWTG-Stroke) quality improvement initiative.

28 Aug 2009

Thickening of neck arteries in healthy middle-aged women with feelings of hopelessness

Healthy middle-aged women with feelings of hopelessness appear to experience thickening of the neck arteries, which can be a precursor to stroke, according to new research out of the University of Minnesota Medical School.

27 Aug 2009

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

The blood thinner warfarin can prevent strokes in most individuals with abnormal heart rhythms, but the drug may have the opposite effect in kidney disease patients on dialysis, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that warfarin should be prescribed with caution in patients with kidney failure.

27 Aug 2009

Health Canada issues marketing approval for NeuroVasx's cPAX Aneurysm Treatment System

NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that it has received approval to market its cPAX Aneurysm Treatment System in Canada from Health Canada's Therapeutic Products Directorate. In addition to Canadian regulatory approval, the cPAX System also received CE Mark in March 2009.

27 Aug 2009

Beta-blockers are less effective at preventing stroke in older people with high blood pressure

27 Aug 2009

Stemedica unveils two of its latest scientific discoveries at the 2009 World Stem Cell Summit

Stemedica Cell Technologies , Inc., ("Stemedica"), a world leader in stem cell research and manufacturing (a licensed manufacturer of clinical grade biological products as licensed by the State of California Food and Drug Branch) continues to advance the stem cell industry with the presentation of two of its latest scientific discoveries at the 2009 World Stem Cell Summit.

27 Aug 2009

Stroke News and Research

Further Reading

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

Thrombogenics issues business update and half year results

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Researchers find link between asymptomatic PAD and cardiovascular events among stroke and TIA patients

NIH panel releases report on the pertinence of family health history information in improving health

Joint Commission urges health care leaders to prevent errors by taking the zero-defect approach

Leicester research reveals the detrimental effects of Beta blockers on central aortic pressures

Kingston General Hospital adopts Sentinelle Medical's new breast imaging system through HTAIP

New rule from CMS for improving stroke patient care in hospitals

Thickening of neck arteries in healthy middle-aged women with feelings of hopelessness

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

Health Canada issues marketing approval for NeuroVasx's cPAX Aneurysm Treatment System

Beta-blockers are less effective at preventing stroke in older people with high blood pressure

Stemedica unveils two of its latest scientific discoveries at the 2009 World Stem Cell Summit

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News